World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
84
Citations
31021
World Ranking
14957
National Ranking
788

Andreas du Bois publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Andreas du Bois sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 481 publications — 55th percentile

55% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Andreas du Bois D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Andreas du Bois sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 84 D-Index — 27th percentile

27% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Andreas du Bois is affiliated with Johannes Gutenberg University of Mainz in Germany. Their research primarily focuses on ovarian cancer diagnosis and treatment within the broader fields of Medicine as well as Biochemistry, Genetics and Molecular Biology. Their work spans several subfields such as Reproductive Medicine, Obstetrics and Gynecology, Oncology, Cancer Research, and Genetics.

The main topics addressed in their research include:

  • Ovarian cancer diagnosis and treatment
  • Endometrial and Cervical Cancer Treatments
  • PARP inhibition in cancer therapy
  • Intraperitoneal and Appendiceal Malignancies
  • BRCA gene mutations in cancer
  • Endometriosis Research and Treatment
  • Cancer-related molecular mechanisms research

Frequently publishing in journals such as:

  • Geburtshilfe und Frauenheilkunde
  • International Journal of Gynecological Cancer
  • Gynecologic Oncology
  • Archives of Gynecology and Obstetrics
  • Ovarian Cancer

Some of the recent papers attributed to Andreas du Bois include:

  • Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20., 2020, Journal of Clinical Oncology
  • Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial, 2020, The Lancet Oncology
  • ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors, 2021, International Journal of Gynecological Cancer
  • Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup, 2022, The Lancet Oncology
  • Quality indicators for advanced ovarian cancer surgery from the European Society of Gynaecological Oncology (ESGO): 2020 update, 2020, International Journal of Gynecological Cancer

Collaborative work is a notable aspect of their research career with frequent co-authors including:

  • Florian Heitz
  • Philipp Harter
  • Beyhan Ataseven
  • Jalid Sehouli
  • Alexander Traut

Best Publications

  • A phase 3 trial of bevacizumab in ovarian cancer.

    Timothy J Perren;Ann Marie Swart;Jacobus Pfisterer;Jonathan A Ledermann

  • A Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian Cancer

    Andreas du Bois;Hans-Joachim Lück;Werner Meier;Hans-Peter Adams

  • Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

    Jacobus Pfisterer;Marie Plante;Ignace Vergote;Andreas du Bois

  • Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk

    Ganna Chornokur;Hui-Yi Lin;Jonathan P. Tyrer;Kate Lawrenson

  • Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study

    Gunter von Minckwitz;Andreas du Bois;Marcus Schmidt;Nicolai Maass

  • Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse

    Eric Pujade-Lauraine;Uwe Wagner;Elisabeth Aavall-Lundqvist;Val Gebski

  • Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study

    Michael Untch;Mahdi Rezai;Sibylle Loibl;Peter A. Fasching

  • Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer

    Stig E. Bojesen;Stig E. Bojesen;Karen A. Pooley;Sharon E. Johnatty;Jonathan Beesley

  • Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups

    Michael Untch;Peter A. Fasching;Gottfried E. Konecny;Stephan Hasmüller

  • Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).

    Gordon John Sampson Rustin;Ignace Vergote;Elizabeth Eisenhauer;Eric Pujade-Lauraine

  • Doxorubicin With Cyclophosphamide Followed by Docetaxel Every 21 Days Compared With Doxorubicin and Docetaxel Every 14 Days As Preoperative Treatment in Operable Breast Cancer: The GEPARDUO Study of the German Breast Group

    Gunter von Minckwitz;Günter Raab;Angelika Caputo;Martin Schütte

  • A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms

    Philipp Harter;Jalid Sehouli;Domenica Lorusso;Alexander Reuss

  • Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer)

    Gordon J. S. Rustin;Michael Quinn;Tate Thigpen;Andreas du Bois

  • Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer

    Andreas Du Bois;Anne Floquet;Jae Weon Kim;Jae Weon Kim;Joern Rau

  • Breast cancer in pregnancy: Recommendations of an international consensus meeting

    Frédéric Amant;Sarah Deckers;Kristel Van Calsteren;Sibylle Loibl

  • Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer: The Multicenter Intergroup Study DESKTOP II. A Project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO

    Philipp Harter;Jalid Sehouli;Alexander Reuss;Annette Hasenburg

  • Gynecologic Cancers in Pregnancy: Guidelines of a Second International Consensus Meeting

    Frédéric Amant;Kristel Van Calsteren;Michael J. Halaska;Jos Beijnen

  • Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer

    Helen J. Mackay;Mark F. Brady;Amit M. Oza;Alexander Reuss

  • Randomized Phase III Trial of Topotecan Following Carboplatin and Paclitaxel in First-line Treatment of Advanced Ovarian Cancer: A Gynecologic Cancer Intergroup Trial of the AGO-OVAR and GINECO

    Jacobus Pfisterer;Béatrice Weber;Alexander Reuss;Rainer Kimmig

  • Capecitabine in Addition to Anthracycline- and Taxane-Based Neoadjuvant Treatment in Patients With Primary Breast Cancer: Phase III GeparQuattro Study

    Gunter von Minckwitz;Mahdi Rezai;Sibylle Loibl;Peter A. Fasching

Frequent Co-Authors

Peter A. Fasching
Peter A. Fasching University of Erlangen-Nuremberg
Graham G. Giles
Graham G. Giles University of Melbourne
Ian G. Campbell
Ian G. Campbell Peter MacCallum Cancer Centre
Jalid Sehouli
Jalid Sehouli Charité - University Medicine Berlin
Susan J. Ramus
Susan J. Ramus University of New South Wales
Daniel W. Cramer
Daniel W. Cramer Brigham and Women's Hospital
Ellen L. Goode
Ellen L. Goode Mayo Clinic
Jenny Chang-Claude
Jenny Chang-Claude German Cancer Research Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative healthcare education pathways can open doors to rewarding careers beyond traditional medical school. For those already holding an RN license, affordable rn to bsn programs allow nurses to complete their Bachelor of Science in Nursing online, often at lower tuition rates.

Those interested in advanced practice may consider direct msn programs online, which offer a streamlined route to a Master’s in Nursing for individuals with non-nursing bachelor’s degrees.

If gaining admission is a concern, many students seek out nursing programs with high acceptance rates, which can ease the competitive pressure of launching a nursing career.

For those drawn to supportive healthcare roles, there are also accredited medical billing and coding schools online with financial aid, making entry into administrative healthcare careers both accessible and affordable.

With a range of online degrees and flexible options, there’s a pathway in healthcare for different backgrounds and career goals.

Best Scientists Citing Andreas du Bois

Trending Scientists

Recently Published Articles